About bolt biotherapeutics inc - BOLT
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
BOLT At a Glance
Bolt Biotherapeutics, Inc.
900 Chesapeake Drive
Redwood City, California 94063
| Phone | 1-650-665-9295 | Revenue | 7.69M | |
| Industry | Pharmaceuticals: Major | Net Income | -63,118,000.00 | |
| Sector | Health Technology | Employees | 52 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
BOLT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.657 |
| Price to Book Ratio | 0.359 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.037 |
| Enterprise Value to Sales | -0.321 |
| Total Debt to Enterprise Value | -10.224 |
BOLT Efficiency
| Revenue/Employee | 147,884.615 |
| Income Per Employee | -1,213,807.692 |
| Receivables Turnover | 6.601 |
| Total Asset Turnover | 0.059 |
BOLT Liquidity
| Current Ratio | 3.201 |
| Quick Ratio | 3.201 |
| Cash Ratio | 3.034 |
BOLT Profitability
| Gross Margin | 71.638 |
| Operating Margin | -887.334 |
| Pretax Margin | -820.78 |
| Net Margin | -820.78 |
| Return on Assets | -48.662 |
| Return on Equity | -74.283 |
| Return on Total Capital | -76.593 |
| Return on Invested Capital | -60.017 |
BOLT Capital Structure
| Total Debt to Total Equity | 44.073 |
| Total Debt to Total Capital | 30.591 |
| Total Debt to Total Assets | 25.302 |
| Long-Term Debt to Equity | 40.138 |
| Long-Term Debt to Total Capital | 27.859 |